A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.
This report aims to provide a comprehensive presentation of the global market for Bi-Specific Antibodies Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bi-Specific Antibodies Therapy. This report contains market size and forecasts of Bi-Specific Antibodies Therapy in global, including the following market information:
Global Bi-Specific Antibodies Therapy Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Bi-Specific Antibodies Therapy market was valued at US$ 3360.6 million in 2022 and is projected to reach US$ 16260 million by 2029, at a CAGR of 25.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.
North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
We surveyed the Bi-Specific Antibodies Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bi-Specific Antibodies Therapy Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Bi-Specific Antibodies Therapy Market Segment Percentages, by Type, 2022 (%)
Fragment-Based Antibodies
IgG-Based Antibodies
Global Bi-Specific Antibodies Therapy Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Bi-Specific Antibodies Therapy Market Segment Percentages, by Application, 2022 (%)
Cancer
Haemophilia
Other Non-Cancer Diseases
Global Bi-Specific Antibodies Therapy Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Bi-Specific Antibodies Therapy Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bi-Specific Antibodies Therapy revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Bi-Specific Antibodies Therapy revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bi-Specific Antibodies Therapy, market overview.
Chapter 2: Global Bi-Specific Antibodies Therapy market size in revenue.
Chapter 3: Detailed analysis of Bi-Specific Antibodies Therapy company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bi-Specific Antibodies Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Bi-Specific Antibodies Therapy Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Bi-Specific Antibodies Therapy Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Bi-Specific Antibodies Therapy Overall Market Size
2.1 Global Bi-Specific Antibodies Therapy Market Size: 2022 VS 2029
2.2 Global Bi-Specific Antibodies Therapy Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Bi-Specific Antibodies Therapy Players in Global Market
3.2 Top Global Bi-Specific Antibodies Therapy Companies Ranked by Revenue
3.3 Global Bi-Specific Antibodies Therapy Revenue by Companies
3.4 Top 3 and Top 5 Bi-Specific Antibodies Therapy Companies in Global Market, by Revenue in 2022
3.5 Global Companies Bi-Specific Antibodies Therapy Product Type
3.6 Tier 1, Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Players in Global Market
3.6.1 List of Global Tier 1 Bi-Specific Antibodies Therapy Companies
3.6.2 List of Global Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Bi-Specific Antibodies Therapy Market Size Markets, 2022 & 2029
4.1.2 Fragment-Based Antibodies
4.1.3 IgG-Based Antibodies
4.2 By Type - Global Bi-Specific Antibodies Therapy Revenue & Forecasts
4.2.1 By Type - Global Bi-Specific Antibodies Therapy Revenue, 2018-2023
4.2.2 By Type - Global Bi-Specific Antibodies Therapy Revenue, 2024-2029
4.2.3 By Type - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Bi-Specific Antibodies Therapy Market Size, 2022 & 2029
5.1.2 Cancer
5.1.3 Haemophilia
5.1.4 Other Non-Cancer Diseases
5.2 By Application - Global Bi-Specific Antibodies Therapy Revenue & Forecasts
5.2.1 By Application - Global Bi-Specific Antibodies Therapy Revenue, 2018-2023
5.2.2 By Application - Global Bi-Specific Antibodies Therapy Revenue, 2024-2029
5.2.3 By Application - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Bi-Specific Antibodies Therapy Market Size, 2022 & 2029
6.2 By Region - Global Bi-Specific Antibodies Therapy Revenue & Forecasts
6.2.1 By Region - Global Bi-Specific Antibodies Therapy Revenue, 2018-2023
6.2.2 By Region - Global Bi-Specific Antibodies Therapy Revenue, 2024-2029
6.2.3 By Region - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Bi-Specific Antibodies Therapy Revenue, 2018-2029
6.3.2 US Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.3.3 Canada Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.3.4 Mexico Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Bi-Specific Antibodies Therapy Revenue, 2018-2029
6.4.2 Germany Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4.3 France Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4.4 U.K. Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4.5 Italy Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4.6 Russia Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4.7 Nordic Countries Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.4.8 Benelux Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Bi-Specific Antibodies Therapy Revenue, 2018-2029
6.5.2 China Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.5.3 Japan Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.5.4 South Korea Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.5.5 Southeast Asia Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.5.6 India Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Bi-Specific Antibodies Therapy Revenue, 2018-2029
6.6.2 Brazil Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.6.3 Argentina Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue, 2018-2029
6.7.2 Turkey Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.7.3 Israel Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.7.4 Saudi Arabia Bi-Specific Antibodies Therapy Market Size, 2018-2029
6.7.5 UAE Bi-Specific Antibodies Therapy Market Size, 2018-2029
7 Bi-Specific Antibodies Therapy Companies Profiles
7.1 Roche
7.1.1 Roche Company Summary
7.1.2 Roche Business Overview
7.1.3 Roche Bi-Specific Antibodies Therapy Major Product Offerings
7.1.4 Roche Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.1.5 Roche Key News & Latest Developments
7.2 Amgen
7.2.1 Amgen Company Summary
7.2.2 Amgen Business Overview
7.2.3 Amgen Bi-Specific Antibodies Therapy Major Product Offerings
7.2.4 Amgen Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.2.5 Amgen Key News & Latest Developments
7.3 Sanofi
7.3.1 Sanofi Company Summary
7.3.2 Sanofi Business Overview
7.3.3 Sanofi Bi-Specific Antibodies Therapy Major Product Offerings
7.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.3.5 Sanofi Key News & Latest Developments
7.4 Pfizer
7.4.1 Pfizer Company Summary
7.4.2 Pfizer Business Overview
7.4.3 Pfizer Bi-Specific Antibodies Therapy Major Product Offerings
7.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.4.5 Pfizer Key News & Latest Developments
7.5 Johnson & Johnson
7.5.1 Johnson & Johnson Company Summary
7.5.2 Johnson & Johnson Business Overview
7.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Major Product Offerings
7.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.5.5 Johnson & Johnson Key News & Latest Developments
7.6 AstraZeneca
7.6.1 AstraZeneca Company Summary
7.6.2 AstraZeneca Business Overview
7.6.3 AstraZeneca Bi-Specific Antibodies Therapy Major Product Offerings
7.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.6.5 AstraZeneca Key News & Latest Developments
7.7 AbbVie
7.7.1 AbbVie Company Summary
7.7.2 AbbVie Business Overview
7.7.3 AbbVie Bi-Specific Antibodies Therapy Major Product Offerings
7.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.7.5 AbbVie Key News & Latest Developments
7.8 Lindis Biotech
7.8.1 Lindis Biotech Company Summary
7.8.2 Lindis Biotech Business Overview
7.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Major Product Offerings
7.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.8.5 Lindis Biotech Key News & Latest Developments
7.9 MacroGenics, Inc
7.9.1 MacroGenics, Inc Company Summary
7.9.2 MacroGenics, Inc Business Overview
7.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Major Product Offerings
7.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.9.5 MacroGenics, Inc Key News & Latest Developments
7.10 Genmab
7.10.1 Genmab Company Summary
7.10.2 Genmab Business Overview
7.10.3 Genmab Bi-Specific Antibodies Therapy Major Product Offerings
7.10.4 Genmab Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.10.5 Genmab Key News & Latest Developments
7.11 Alphamab Co. Ltd
7.11.1 Alphamab Co. Ltd Company Summary
7.11.2 Alphamab Co. Ltd Business Overview
7.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Major Product Offerings
7.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.11.5 Alphamab Co. Ltd Key News & Latest Developments
7.12 Akeso, Inc.
7.12.1 Akeso, Inc. Company Summary
7.12.2 Akeso, Inc. Business Overview
7.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Major Product Offerings
7.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue in Global Market (2018-2023)
7.12.5 Akeso, Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Bi-Specific Antibodies Therapy Market Opportunities & Trends in Global Market
Table 2. Bi-Specific Antibodies Therapy Market Drivers in Global Market
Table 3. Bi-Specific Antibodies Therapy Market Restraints in Global Market
Table 4. Key Players of Bi-Specific Antibodies Therapy in Global Market
Table 5. Top Bi-Specific Antibodies Therapy Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Bi-Specific Antibodies Therapy Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Bi-Specific Antibodies Therapy Revenue Share by Companies, 2018-2023
Table 8. Global Companies Bi-Specific Antibodies Therapy Product Type
Table 9. List of Global Tier 1 Bi-Specific Antibodies Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Bi-Specific Antibodies Therapy Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Bi-Specific Antibodies Therapy Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Bi-Specific Antibodies Therapy Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2024-2029
Table 30. Roche Company Summary
Table 31. Roche Bi-Specific Antibodies Therapy Product Offerings
Table 32. Roche Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 33. Roche Key News & Latest Developments
Table 34. Amgen Company Summary
Table 35. Amgen Bi-Specific Antibodies Therapy Product Offerings
Table 36. Amgen Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 37. Amgen Key News & Latest Developments
Table 38. Sanofi Company Summary
Table 39. Sanofi Bi-Specific Antibodies Therapy Product Offerings
Table 40. Sanofi Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 41. Sanofi Key News & Latest Developments
Table 42. Pfizer Company Summary
Table 43. Pfizer Bi-Specific Antibodies Therapy Product Offerings
Table 44. Pfizer Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 45. Pfizer Key News & Latest Developments
Table 46. Johnson & Johnson Company Summary
Table 47. Johnson & Johnson Bi-Specific Antibodies Therapy Product Offerings
Table 48. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 49. Johnson & Johnson Key News & Latest Developments
Table 50. AstraZeneca Company Summary
Table 51. AstraZeneca Bi-Specific Antibodies Therapy Product Offerings
Table 52. AstraZeneca Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 53. AstraZeneca Key News & Latest Developments
Table 54. AbbVie Company Summary
Table 55. AbbVie Bi-Specific Antibodies Therapy Product Offerings
Table 56. AbbVie Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 57. AbbVie Key News & Latest Developments
Table 58. Lindis Biotech Company Summary
Table 59. Lindis Biotech Bi-Specific Antibodies Therapy Product Offerings
Table 60. Lindis Biotech Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 61. Lindis Biotech Key News & Latest Developments
Table 62. MacroGenics, Inc Company Summary
Table 63. MacroGenics, Inc Bi-Specific Antibodies Therapy Product Offerings
Table 64. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 65. MacroGenics, Inc Key News & Latest Developments
Table 66. Genmab Company Summary
Table 67. Genmab Bi-Specific Antibodies Therapy Product Offerings
Table 68. Genmab Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 69. Genmab Key News & Latest Developments
Table 70. Alphamab Co. Ltd Company Summary
Table 71. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product Offerings
Table 72. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 73. Alphamab Co. Ltd Key News & Latest Developments
Table 74. Akeso, Inc. Company Summary
Table 75. Akeso, Inc. Bi-Specific Antibodies Therapy Product Offerings
Table 76. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue (US$, Mn) & (2018-2023)
Table 77. Akeso, Inc. Key News & Latest Developments
List of Figures
Figure 1. Bi-Specific Antibodies Therapy Segment by Type in 2022
Figure 2. Bi-Specific Antibodies Therapy Segment by Application in 2022
Figure 3. Global Bi-Specific Antibodies Therapy Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Bi-Specific Antibodies Therapy Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Bi-Specific Antibodies Therapy Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Bi-Specific Antibodies Therapy Revenue in 2022
Figure 8. By Type - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 9. By Application - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 10. By Type - Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 12. By Application - Global Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 14. By Region - Global Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 15. By Country - North America Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 16. US Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 20. Germany Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 21. France Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 28. China Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 32. India Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 34. Brazil Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Bi-Specific Antibodies Therapy Revenue Market Share, 2018-2029
Figure 37. Turkey Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Bi-Specific Antibodies Therapy Revenue, (US$, Mn), 2018-2029
Figure 41. Roche Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Amgen Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Sanofi Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Pfizer Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Johnson & Johnson Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. AstraZeneca Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. AbbVie Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Lindis Biotech Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Genmab Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Akeso, Inc. Bi-Specific Antibodies Therapy Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
